373 related articles for article (PubMed ID: 34739635)
1. Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial.
Bonneville-Levard A; Frappaz D; Tredan O; Lavergne E; Corset V; Agrapart V; Chabaud S; Pissaloux D; Wang Q; Attignon V; Cartalat S; Ducray F; Thomas-Maisonneuve L; Honnorat J; Meyronet D; Taillandier L; Blonski M; Viari A; Baudet C; Sohier E; Lantuejoul S; Paindavoine S; Treilleux I; Rodriguez C; Pérol D; Blay JY
Med Oncol; 2021 Nov; 39(1):4. PubMed ID: 34739635
[TBL] [Abstract][Full Text] [Related]
2. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
Trédan O; Wang Q; Pissaloux D; Cassier P; de la Fouchardière A; Fayette J; Desseigne F; Ray-Coquard I; de la Fouchardière C; Frappaz D; Heudel PE; Bonneville-Levard A; Fléchon A; Sarabi M; Guibert P; Bachelot T; Pérol M; You B; Bonnin N; Collard O; Leyronnas C; Attignon V; Baudet C; Sohier E; Villemin JP; Viari A; Boyault S; Lantuejoul S; Paindavoine S; Treillleux I; Rodriguez C; Agrapart V; Corset V; Garin G; Chabaud S; Pérol D; Blay JY;
Ann Oncol; 2019 May; 30(5):757-765. PubMed ID: 30865223
[TBL] [Abstract][Full Text] [Related]
3. Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
Varnier R; Le Saux O; Chabaud S; Garin G; Sohier E; Wang Q; Paindavoine S; Pérol D; Baudet C; Attignon V; Pissaloux D; Heudel P; You B; Leyronnas C; Collard O; Trédan O; Bonnin N; Long J; Jacquin JP; Cassier PA; Derbel O; Freyer G; Viari A; Blay JY; Ray-Coquard I
Eur J Cancer; 2019 Sep; 118():156-165. PubMed ID: 31351267
[TBL] [Abstract][Full Text] [Related]
4. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
5. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
[No Abstract] [Full Text] [Related]
6. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
[TBL] [Abstract][Full Text] [Related]
7. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of extensive molecular profiling in advanced cancer patients.
Cousin S; Grellety T; Toulmonde M; Auzanneau C; Khalifa E; Laizet Y; Tran K; Le Moulec S; Floquet A; Garbay D; Robert J; Hostein I; Soubeyran I; Italiano A
J Hematol Oncol; 2017 Feb; 10(1):45. PubMed ID: 28179005
[TBL] [Abstract][Full Text] [Related]
9. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
10. Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
Kim SY; Kim JH; Kim TY; Park SR; Yoon S; Lee S; Lee SH; Kim TM; Han SW; Kim HR; Yun H; Lee S; Kim J; Choi YL; Choi KS; Chae H; Ryu H; Lee GW; Zang DY; Ahn JB
BMC Cancer; 2024 May; 24(1):574. PubMed ID: 38724991
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of gliomas: potential therapeutic implications.
Alentorn A; Duran-Peña A; Pingle SC; Piccioni DE; Idbaih A; Kesari S
Expert Rev Anticancer Ther; 2015; 15(8):955-62. PubMed ID: 26118895
[TBL] [Abstract][Full Text] [Related]
12. Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center Experience.
Seet AOL; Tan AC; Tan TJ; Ng MCH; Tai DWM; Lam JYC; Tan GS; Gogna A; Too CW; Tan BS; Takano A; Lim A; Lim TH; Lim ST; Dent RA; Ang MK; Yap YS; Tan IBH; Choo SP; Toh CK; Lim EH; Farid M; Skanderup AJ; Iyer NG; Lim WT; Tan EH; Lim TKH; Tan DSW
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250396
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.
Blumenthal DT; Dvir A; Lossos A; Tzuk-Shina T; Lior T; Limon D; Yust-Katz S; Lokiec A; Ram Z; Ross JS; Ali SM; Yair R; Soussan-Gutman L; Bokstein F
J Neurooncol; 2016 Oct; 130(1):211-219. PubMed ID: 27531351
[TBL] [Abstract][Full Text] [Related]
14. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
Yang JW; Choi YL
Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
[TBL] [Abstract][Full Text] [Related]
15. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
16. LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study.
Kong BY; Sim HW; Nowak AK; Yip S; Barnes EH; Day BW; Buckland ME; Verhaak R; Johns T; Robinson C; Thomas MA; Giardina T; Lwin Z; Scott AM; Parkinson J; Jeffree R; Lourenco RA; Hovey EJ; Cher LM; Kichendasse G; Khasraw M; Hall M; Tu E; Amanuel B; Koh ES; Gan HK
BMJ Open; 2021 Dec; 11(12):e054075. PubMed ID: 37185327
[TBL] [Abstract][Full Text] [Related]
17. Comparative genomic and proteomic analysis of high grade glioma primary cultures and matched tumor in situ.
Howley R; Kinsella P; Buckley PG; Alcock L; Jansen M; Heffernan J; Stallings RL; Brett FM; Amberger-Murphy V; Farrell MA
Exp Cell Res; 2012 Oct; 318(17):2245-56. PubMed ID: 22705586
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer.
Kondo T; Matsubara J; Quy PN; Fukuyama K; Nomura M; Funakoshi T; Doi K; Sakamori Y; Yoshioka M; Yokoyama A; Tamaoki M; Kou T; Hirohashi K; Yamada A; Yamamoto Y; Minamiguchi S; Nishigaki M; Yamada T; Kanai M; Matsumoto S; Muto M
Cancer Sci; 2021 Jan; 112(1):296-304. PubMed ID: 33007138
[TBL] [Abstract][Full Text] [Related]
19. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
20. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
